Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin

다국어 초록 (Multilingual Abstract)

Over the last decade, physiologically based pharmacokinetics (PBPK) application has been extended significantly not only to predicting preclinical/ human PK but also to evaluating the drug-drug interaction (DDI) liability at the drug discovery or development stage. Herein, we describe a case study to illustrate the use of PBPK approach in predicting human PK as well as DDI using in silico, in vivo and in vitro derived parameters. This case was composed of five steps such as: simulation, verification, understanding of parameter sensitivity, optimization of the parameter and final evaluation. Caffeine and ciprofloxacin were used as tool compounds to demonstrate the “fit for purpose” application of PBPK modeling and simulation for this study. Compared to caffeine, the PBPK modeling for ciprofloxacin was challenging due to several factors including solubility, permeability, clearance and tissue distribution etc. Therefore, intensive parameter sensitivity analysis (PSA) was conducted to optimize the PBPK model for ciprofloxacin. Overall, the increase in Cmax of caffeine by ciprofloxacin was not significant. However, the increase in AUC was observed and was proportional to the administered dose of ciprofloxacin. The predicted DDI and PK results were comparable to observed clinical data published in the literatures. This approach would be helpful in identifying potential key factors that could lead to significant impact on PBPK modeling and simulation for challenging compounds.

참고문헌 (Reference)

• 1 Baneyx G, "Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions" 4 : 681-693, 2012
• 2 Ripp SL, "Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4induction" 34 : 1742-1748, 2006
• 3 Almond LM, "Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction" 10 : 420-432, 2009
• 4 Kato M, "The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes" 20 : 236-243, 2005
• 5 Bjornsson TD, "The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective" 43 : 443-469, 2003
• 6 Jones HM, "Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling" 50 : 331-347, 2011
• 7 Kozawa M, "Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay" 37 : 1234-1241, 2009
• 8 Zhang T, "Prospective predictions of human pharmacokinetics for eighteen compounds" 104 : 2795-2806, 2015
• 9 Sawada Y, "Prediction of the volumes of distribution of basic drugs in humans based on data from animals" 12 : 587-596, 1984
• 10 Yamazaki S, "Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans : physiologically based pharmacokinetic model versus traditional one-compartment model" 39 : 383-393, 2011
• 11 Hosea NA, "Predicting pharmacokinetic profiles using in silico derived parameters" 10 : 1207-1215, 2013
• 12 Bungay PJ, "Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist" 39 : 1396-1405, 2011
• 13 Baneyx G, "Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human : influence of time between substrate and inducer administration" 56 : 1-15, 2014
• 14 Valizadeh H, "Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy vol unteers" 62 : 566-570, 2012
• 15 Jones HM, "Modelling and PBPK simulation in drug discovery" 11 : 155-166, 2009
• 16 Shou M, "Modeling, prediction, and in vitro in vivo correlation of CYP3A4induction" 36 : 2355-2370, 2008
• 17 Boxenbaum H, "Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm" 15 : 1071-1121, 1984
• 18 Staib AH, "Interaction between quinolones and caffeine" (34 Suppl 1) : 170-174, 1987
• 19 Healy DP, "Interaction between oral ciprofloxacin and caffeine in normal volunteers" 33 : 474-478, 1989
• 20 Krayenbühl JC, "Drugdrug interactions of new active substances : mibefradil example" 55 : 559-565, 1999
• 21 Zhang L, "Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes" 29 : 1507-1514, 2008
• 22 Einolf HJ, "Comparison of different approaches to predict metabolic drug-drug interactions" 37 : 1257-1294, 2007
• 23 Zhao P, "Applications of physiologically based pharmacokinetic(PBPK)modeling and simulation during regulatory review" 89 : 259-267, 2011
• 24 Jones HM, "Application of PBPK modelling in drug discovery and development at Pfizer" 42 : 94-106, 2012
• 25 Heikkinen AT, "Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates-an evaluation and case study using GastroPlus" 47 : 375-386, 2012
• 26 Chen Y, "Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics : strategy and approach during the drug discovery phase with four case studies" 33 : 85-98, 2012
• 27 Poulin P, "A priori prediction of tissue : plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery" 89 : 16-35, 2000
• 28 Guo H, "A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A inductionmediated drug-drug interactions" 102 : 2819-2836, 2013
• 29 Yu LX, "A compartmental absorption and transit model for estimating oral drug absorption" 186 : 119-125, 1999
• 30 Fahmi OA, "A combined model for predicting CYP3A4 clinical net drugdrug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro" 36 : 1698-1708, 2008
• 31 Harder S, "4-quinolones inhibit biotransformation of caffeine" 35 : 651-656, 1988